Anavex Life Sciences (NASDAQ:AVXL – Free Report) had its price target decreased by HC Wainwright from $54.00 to $40.00 in a research report released on Wednesday, Benzinga reports. HC Wainwright currently has a buy rating on the biotechnology company’s stock. HC Wainwright also issued estimates for Anavex Life Sciences’ Q1 2024 earnings at ($0.15) EPS, […]